ArticleProceedings of the National Academy of Sciences of the United States of America2026
Hepatitis B virus covalently closed circular DNA formation in murine hepatic cells uncovers a late entry block.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- SCARF2 Mediates Intracellular Trafficking and Nucleocapsid Release of Hepatitis B Virus Within Hepatocytes.Journal of clinical and translational hepatology · 2026Article
- Cell-based platforms for antiviral screening against hepatitis B virus: advantages, limitations, and future perspectives.Antiviral research · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Chronic hepatitis B virus (HBV) infection affects nearly 300 million people worldwide. Progress in understanding HBV immunopathogenesis and developing curative therapies has been hindered by the lack of suitable small animal models. HBV exhibits strict host and tissue tropism, with productive infection largely restricted to human and chimpanzee hepatocytes. Murine hepatocytes are resistant to HBV infection, even with ectopic expression of the human HBV entry receptor sodium taurocholate cotransporting polypeptide (huNTCP), because they apparently fail to form covalently closed circular DNA (cccDNA), the viral episome required for productive infection and persistence. To investigate the mechanisms restricting HBV infection in murine cells, we developed a piggyBac transposon-based system that efficiently generates inducible stable cell lines supporting HBV replication and cccDNA formation via intracellular amplification-a pathway that shares similar nucleocapsid uncoating and nuclear import of relaxed circular DNA (rcDNA) that occur during de novo infection. Remarkably, all tested murine hepatocyte and hepatoma cell lines, across multiple mouse genetic backgrounds, supported cccDNA formation at levels comparable to human cells, indicating that nucleocapsid uncoating and rcDNA nuclear import are not limited in mice. Given that huNTCP-expressing murine hepatocytes support hepatitis D virus infection, which shares early entry events with HBV, our findings reveal that the dominant restriction to HBV infection in huNTCP-expressing murine hepatocytes lies at a late entry step preceding nucleocapsid uncoating. By defining this mechanistic block, our study advances understanding of HBV host tropism and provides a foundation for facilitating development of fully HBV-susceptible mouse models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.